
CORRECTION





Correction: The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥1 line of endocrine therapy: systematic review and meta-analysis

Xiewei Huang^{1,3†}, Yushuai Yu^{1,3†}, Shiping Luo^{1,3}, Wenfen Fu^{1,3}, Jie Zhang^{1,2,3*} and Chuangui Song^{1,2,3*}

Correction: BMC Cancer 24, 21 (2024) https://doi.org/10.1186/s12885-023-11722-4

Following publication of the original article [1], the authors reported an error in the fourth sentence of the first paragraph of the "Safety" sub-section of the "Results" section (copied and in bold below for your ease of reference): The proportion of drug discontinuation caused by TEAEs in the three treatment groups of SERENA-2 was 14.9% (camizestrant 75 mg), 21.9% (camizestrant 150 mg), and 4.1% (standard-of-care ET), respectively.

 $^{\dagger}\mathrm{X}i\mathrm{ewei}$ Huang and Yushuai Yu contributed equally to this work and share first authorship.

The online version of the original article can be found at https://doi. org/10.1186/s12885-023-11722-4.

*Correspondence: Jie Zhang zjie1979@gmail.com Chuangui Song Songcg1971@hotmail.com ¹Department of Breast Surgery, Fujian Medical University Union Hospital, No. 29, Xin Quan Road, Gulou District, 350001 Fuzhou, Fujian Province, China ²Department of General Surgery, Fujian Medical University Union Hospital, 350001 Fuzhou, Fujian Province, China ³Breast Surgery Institute, Fujian Medical University, 350001 Fuzhou, Fujian Province, China We have quoted the proportion of TEAEs leading to dose interruption, rather than those leading to discontinuation which is an error. The correct sentence should be: The proportion of drug discontinuation caused by treatment related AEs (TRAEs) in the three treatment groups of SERENA-2 was 2.7% (camizestrant 75 mg), 0% (camizestrant 150 mg), and 0% (fulvestrant as standard-of-care ET), respectively.

The original article [1] has been corrected.

Published online: 13 February 2024

References

 Huang X, Yu Y, Luo S, et al. The value of oral selective estrogen receptor degraders in patients with HR-positive, HER2-negative advanced breast cancer after progression on ≥ 1 line of endocrine therapy: systematic review and meta-analysis. BMC Cancer. 2024;24:21. https://doi.org/10.1186/ s12885-023-11722-4.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.